Breathe Well Live Well
|
Positive Results for Reslizumab in Asthma Trials
Monthly Prescribing Reference Teva announced positive results from its Phase 3 studies of reslizumab in patients with uncontrolled moderate to severe asthma with elevated eosinophils, treated with standard of care therapies. Reslizumab is an investigational humanized monoclonal … Teva's Asthma Drug 'Significantly' Improves Lung Function In Phase 3 Trials |
View full post on asthma – Google News
Globes |
Teva finds positive results in advanced trials for asthma drug
Yahoo News TEL AVIV (Reuters) – Teva Pharmaceutical Industries said a drug under development had positive results in reducing the frequency of clinical asthma exacerbations in two advanced trials in patients with moderate to severe asthma. Reslizumab, an … Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies Teva reports positive Phase III asthma drug results |
View full post on asthma – Google News
Globes |
Teva finds positive results in advanced trials for asthma drug
Reuters Reslizumab, an investigational antibody, showed statistically significant reductions in the frequency of asthma exacerbations – episodes of progressively worsening shortness of breath, coughing, wheezing, and chest tightness – compared to patients … Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies Teva reports positive Phase III asthma drug results |
View full post on asthma – Google News
Reuters UK |
Giro stage winner Ulissi tests positive for excessive amount of anti-asthma drug
road.cc Lampre-Merida has revealed that Diego Ulissi, winner of two stages at last month's Giro d'Italia, has been notified by the UCI of an adverse analytical finding for an excessive amount of the anti-asthma drug salbutamol during the race. Both the rider … Diego Ulissi had 'abnormal' level of asthma drug in Giro d'Italia Giro stage winner Ulissi fails drugs test Diego Ulissi fails anti-doping test from Giro d'Italia |
View full post on asthma – Google News
|
Amgen Posts Positive Phase I Results For Asthma Drug
BioResearch Online (press release) Amgen reported positive results from the Phase I study showing that inhibiting thymic stromal lymphopoietin (TSLP) could be useful in the treatment of asthma. TSLP is a cytokine considered to be a key driver of the allergic inflammation that … Anti-thymic stromal lymphopoietin therapy reduced allergy-induced … |
View full post on asthma – Google News
|
Atopix reports positive results from Phase IIb asthma study with OC459 compound
News-Medical.net Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma … |
View full post on asthma – Google News
|
Teva's DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPD
Pharmaceutical Business Review DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid for the treatment of underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting … Teva's Symbicort generic backed for EU approval 10 new medicines recommended for approval in Europe |
View full post on asthma – Google News
|
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …
RTT News DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 … EU Agency backs respiratory drugs for approval EMA Backs Generic Versions of AstraZeneca's Symbicort |
View full post on asthma – Google News
|
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …
NASDAQ DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 … UPDATE 1-EU Agency backs respiratory drugs for approval EMA Backs Generic Versions of AstraZeneca's Symbicort |
View full post on asthma – Google News
|
Asthma care improvement initiative shows positive results among teens
Healio Recent data show that a quality improvement initiative, created by researchers at Cincinnati Children's Hospital, significantly improved asthma control and outcomes among high-risk adolescents. The study was conducted from 2007 to 2011 and included 322 … |
View full post on asthma – Google News